Giant cell arteritis

Current Opinion in Rheumatology

Volumn 14, Issue 1, 2002, Pages 3-10

  Levine, Stuart M ^a   Hellmann, David B ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTOKINE; METHOTREXATE; PREDNISONE;

AXILLARY ARTERY; BIOPSY; BLINDNESS; CLAUDICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOPPLER ECHOGRAPHY; DOUBLE BLIND PROCEDURE; EARLY DIAGNOSIS; GIANT CELL ARTERITIS; HEADACHE; HUMAN; JAW DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RHEUMATIC POLYMYALGIA; SUBCLAVIAN ARTERY; SYSTEMIC VASCULITIS; TEMPORAL ARTERY; THORACIC AORTA ANEURYSM; VISUAL DISORDER;

ANTIRHEUMATIC AGENTS; HUMANS; METHOTREXATE; RISK FACTORS; TEMPORAL ARTERITIS;

EID: 0036140635     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200201000-00002     Document Type: Review

References (72)

1. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: Trend over an 18 year period
2. Giant cell arteritis and polymyalgia rheumatica
3. Epidemiology of biopsy-positive giant cell arteritis: An overview
4. Giant cell arteritis
5. Treatment of corticosteroid-resistant giant cell arteritis
6. Epidemiology of polymyalgia rheumatica
7. Giant cell arteritis and cardiovascular risk factors
8. Treatment of giant cell arteritis: Interleukin-6 as a biologic marker of disease activity
9. Arterial wall injury in giant cell arteritis
10. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis
11. Pathogenesis of giant cell arteritis
12. Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis: Evidence for two components of the disease
13. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis
14. The pathogenesis of giant cell arteritis: Morphological aspects
15. IFN-gamma action in the media of the great elastic arteries: A novel immunoprivileged site
16. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis
17. Disease patterns and tissue cytokine profiles in giant cell arteritis
18. CD4+ and CD8+ T cell expansions using selected TCR V and J gene segments at the onset of giant cell arteritis
19. The HLA-DRB1 locus as a genetic component in giant cell arteritis: Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule
20. Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: A review
21. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association
22. Biopsy-negative giant cell arteritis: Clinical spectrum and predictive factors for positive temporal artery biopsy
23. Familial aggregation of polymyalgia rheumatica and giant cell arteritis: Genetic and T cell repertoire analysis
24. Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms
25. Disease pattern in cranial and large-vessel giant cell arteritis
26. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica
27. Human parvovirus and giant cell arteritis: A selective arteritic impact?
28. Giant cell arteritis and polymyalgia rheumatica: Role of viral infections
29. Giant cell arteritis after influenza vaccination
30. Cavernous sinus syndrome due to vaccination-induced giant cell arteritis
31. Detection of Chalmydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells
32. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark: Association with epidemics of Mycoplasma pneumoniae infection
33. Temporal arteritis associated with Chalmydia pneumoniae DNA detected in an artery specimen
34. Temporal arteritis
35. Giant cell arteritis: Including temporal arteritis and polymyalgia rheumatica
36. Giant cell arteritis
37. Giant cell (cranial) arteritis: A clinical review
38. Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin
39. Neurologic complications of giant cell (temporal) arteritis
40. Neurologic disease in biopsy-proven giant cell (temporal) arteritis
41. The spectrum of conditions mimicking polymyalgia rheumatica in northwestern Spain
42. Presentation of occult giant cell arteritis
43. Occult manifestations of giant cell arteritis
44. Nonclassical organ involvement in temporal arteritis
45. Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate
46. Systemic vasculitis presenting as a tumorlike lesion. Four case reports and an analysis of 79 reported cases
47. Lower limb giant cell arteritis and temporal arteritis: Followup of 8 cases
48. Large artery involvement in giant cell (temporal) arteritis
49. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: A population-based study
50. Study of 52 patients with idiopathic aortitis from a cohort of 1,204 surgical cases
51. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: Evidence for inflammation of the aortic arch
52. Giant call arteritis with low erythrocyte sedimentation rate: Frequency of occurrence in a population-based study
53. Temporal arteritis with normal erythrocyte sedimentation rates presenting as occipital neuralgia
54. Temporal arteritis without an elevated erythrocyte sedimentation rate: Case report and review of the literature
55. Temporal arteritis with low erythrocyte sedimentation rate: A review of five cases
56. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis
57. Small-vessel vasculitis surrounding a spared temporal artery
58. Imaging findings in extracranial (giant cell) temporal arteritis
59. Color duplex ultrasonography in the diagnosis of temporal arteritis
60. Doppler ultrasonography in the diagnosis of giant cell arteritis
61. Magnetic resonance imaging of large vessel vasculitis
62. Giant cell arteritis and magnetic resonance angiography
63. Imaging of giant cell arteritis: Evidence of splenic involvement using FDG positron emission tomography
64. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis
65. Steroid sparing therapeutic approaches to polymyalgia rheumatica-giant cell arteritis: State of the art perspectives
66. Combined treatment of giant-cell arteritis with methotrexate and prednisone
67. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: Comparison in a prospective study
68. An alternate-day corticosteroid regimen in maintenance-therapy of giant cell arteritis
69. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: A one year followup study of 164 patients
70. Azathioprine in giant cell arteritis/polymyalgia rheumatica: A double-blind study
71. A multicenter randomized, double-blind controlled study of methotrexate in giant cell arteritis
72. Temporal arteritis: A 25-year epidemiologic, clinical, and pathologic study